The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

Nevertheless, Novo Nordisk’s first-quarter earnings match, while revenues miss. Ozempic and Rybelsus for ... s shares have outperformed the Zacks Chemical - Specialty industry over the past ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago. Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable ...

The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the ...

The foundation also pushed for stronger board representation. Also Read: Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds NVO stock has lost close to 50% ...

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO), opens new tab on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the ...